Ablynx has received a $533,600 milestone payment triggered by the approval of an IND application for the Phase I trial for a Nanobody licensed to Novartis. This is the first development candidate resulting from the licensing agreement between the two companies from July 2010. Under the agreement, Novartis obtained licenses to develop and commercialize Nanobodies against two targets. Since July 2010, Novartis has full responsibility for the continued development of both programs and Ablynx is el...